drugset
drugset / Trial / NCT00865228

Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

NCT00865228 ↗

Phase 2 Terminated 224 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.

Timeline

Start
2007-07
Primary completion
2007-11
Completion
2007-11

Outcome

Outcome not reported

Stopped: “Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapaquistat acetate Small molecule 50 mg Oral
Subject Lapaquistat acetate Small molecule 100 mg Oral

Indications

hyperlipoproteinemia